$35.85 +0.26 (%) AMAG Pharmaceuticals Inc - NASDAQ

Nov. 21, 2014 | 01:59 PM

Partner Headlines

  1. Events for the Week of Nov. 17-21, 2014

    Benzinga | Nov. 17, 2014 | 13:13PM EST
  2. GoPro Among Top 6 Stocks Outperforming The Market

    IBD | Oct. 7, 2014 | 08:02AM EST
  3. Benzinga's Top Upgrades

    Benzinga | Sep. 30, 2014 | 08:39AM EST
  4. FBR Capital Upgrades AMAG Pharmaceuticals To Outperform

    Benzinga | Sep. 30, 2014 | 08:19AM EST
  5. Benzinga's Volume Movers

    Benzinga | Sep. 29, 2014 | 10:17AM EST
  6. Morning Market Movers

    Benzinga | Sep. 29, 2014 | 09:36AM EST
  7. US Stock Futures Down Ahead Of Economic Data

    Benzinga | Sep. 29, 2014 | 07:37AM EST
  8. AMAG Pharma Announces Publication of Data from Trial of MuGard in the Journal Cancer

    Benzinga | Apr. 28, 2014 | 08:15AM EST
  9. Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio

    Benzinga | Feb. 13, 2014 | 04:18AM EST
  10. Benzinga's Top #PreMarket Losers

    Benzinga | Jan. 22, 2014 | 08:26AM EST
  11. US Stock Futures Down Ahead Of Earnings

    Benzinga | Jan. 22, 2014 | 07:15AM EST
  12. UPDATE: AMAG Pharmaceuticals Receives CRL from FDA for Supplemental NDA for Feraheme for Broader IDA Indication

    Benzinga | Jan. 22, 2014 | 06:57AM EST
  13. Earnings Scheduled For January 15, 2014

    Benzinga | Jan. 15, 2014 | 04:18AM EST
  14. Market Wrap For December 31: Markets End The Year On A Positive Note

    Benzinga | Dec. 31, 2013 | 16:29PM EST
  15. AMAG Pharmaceuticals Update Announces Preliminary 2012 Financial Results and 2013 Financial Guidance

    Benzinga | Jan. 6, 2013 | 05:34AM EST
  16. AMAG Pharmaceuticals, Inc. (AMAG) EVP, COO Frank E Thomas sells 10,000 Shares

    GuruFocus | Jan. 4, 2013 | 11:08AM EST
  17. AMAG Pharma Submits Supplemental NDA for Feraheme

    Benzinga | Dec. 24, 2012 | 01:32AM EST
  18. AMAG Pharma Reports New Data from Ferumoxytol Pivotal Phase III Broad Iron Deficiency Anemia Program

    Benzinga | Dec. 10, 2012 | 04:17AM EST
  19. AMAG Pharmaceuticals Inc. (AMAG) EVP, COO Frank E Thomas sells 5,000 Shares

    GuruFocus | Dec. 4, 2012 | 10:56AM EST
  20. AMAG Pharmaceuticals Inc. (AMAG) EVP, COO Frank E Thomas sells 5,000 Shares

    GuruFocus | Dec. 4, 2012 | 08:33AM EST
  21. AMAG Pharmaceuticals, Inc. (AMAG) EVP, COO Frank E Thomas sells 5,000 Shares

    GuruFocus | Dec. 4, 2012 | 01:36AM EST
  22. Rienso Receives Swiss Marketing Authorization for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease

    Benzinga | Sep. 5, 2012 | 02:17AM EST
  23. AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 7, 2012 | 10:23AM EST
  24. Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Cash

    Benzinga | Aug. 1, 2012 | 19:05PM EST
  25. Financial Breakfast: Morning News Summary for July 18, 2012

    Benzinga | Jul. 18, 2012 | 01:20AM EST
  26. AMAG Pharmaceuticals Announces Positive Preliminary Results from its Phase III Study Evaluating Feraheme Compared to Placebo in Patients with Iron Deficiency Anemia

    Benzinga | Jul. 18, 2012 | 00:48AM EST
  27. Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Cash

    Benzinga | Jul. 12, 2012 | 20:47PM EST
  28. AMAG Pharmaceuticals Realigns Operating Cost Structure; Expects to Reduce Workforce by 45 Position by the end of 2012

    Benzinga | Jun. 25, 2012 | 10:31AM EST
  29. UPDATE: Ladenburg Thalmann Upgrades AMAG Pharmaceuticals to Buy

    Benzinga | May. 17, 2012 | 04:44AM EST
  30. Benzinga's Top Downgrades With Color for May 10, 2012

    Benzinga | May. 10, 2012 | 05:54AM EST
  31. UPDATE: Ladenburg Thalmann Downgrades AMAG Pharmaceuticals; Removes PT

    Benzinga | May. 10, 2012 | 04:24AM EST
  32. AMAG Pharmaceuticals Appoints William Heiden as President and Chief Executive Officer

    Benzinga | May. 9, 2012 | 10:09AM EST
  33. UPDATE: Ladenburg Thalmann Lowers AMAG Pharmaceuticals PT

    Benzinga | Mar. 6, 2012 | 01:37AM EST
  34. AMAG Pharmaceuticals Reports Mixed Q4 Results

    Benzinga | Mar. 5, 2012 | 09:31AM EST
  35. AMAG Pharmaceuticals Reports Mixed Q4 Results

    Benzinga | Mar. 5, 2012 | 09:30AM EST
  36. UPDATE: JP Morgan Downgrades AMAG Pharmaceuticals to Underweight, Reduces PT to $12

    Benzinga | Jan. 23, 2012 | 04:25AM EST
  37. JP Morgan Downgrades AMAG Pharmaceuticals to Underweight

    Benzinga | Jan. 23, 2012 | 00:52AM EST
  38. JP Morgan Downgrades AMAG Pharmaceuticals to Underweight

    Benzinga | Jan. 23, 2012 | 00:52AM EST
  39. JP Morgan Downgrades AMAG Pharmaceuticals to Underweight

    Benzinga | Jan. 23, 2012 | 00:51AM EST
  40. McNicoll Lewis Vlak Lowers PT on AMAG Pharmaceuticals to $21

    Benzinga | Jan. 17, 2012 | 07:38AM EST
  41. AMAG Pharmaceuticals Sees Q4 Revenues of $14.3-15.0M vs $16.11M

    Benzinga | Jan. 9, 2012 | 00:32AM EST
  42. Top 4 NASDAQ Stocks In Diagnostic Substances Industry With The Highest Cash

    Benzinga | Jan. 4, 2012 | 21:01PM EST
  43. McNicoll Lewis & Vlak Raises PT on AMAG Pharmaceuticals to $23

    Benzinga | Dec. 12, 2011 | 06:47AM EST
  44. Health Canada Approves Feraheme to Treat Iron Deficiency Anemia in Adults with Chronic Kidney Disease

    Benzinga | Dec. 12, 2011 | 00:48AM EST
  45. AMAG Pharmaceuticals Announces Preliminary Data Regarding the Safety and Efficacy of a Single Infusion of 1020 mg Ferumoxytol in Patients with Iron Deficiency Anemia

    Benzinga | Dec. 12, 2011 | 00:43AM EST
Trading Center